Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Chinese Patent Office
Baxter
Farmers Insurance
Julphar
McKinsey

Generated: April 25, 2019

DrugPatentWatch Database Preview

Shionogi Inc Company Profile

« Back to Dashboard

Summary for Shionogi Inc
International Patents:113
US Patents:10
Tradenames:7
Ingredients:7
NDAs:7
Patent Litigation for Shionogi Inc: See patent lawsuits for Shionogi Inc

Drugs and US Patents for Shionogi Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Shionogi Inc MULPLETA lusutrombopag TABLET;ORAL 210923-001 Jul 31, 2018 RX Yes Yes 8,530,668 ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Shionogi Inc DORIBAX doripenem INJECTABLE;INTRAVENOUS 022106-001 Oct 12, 2007 DISCN Yes No 8,247,402 ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Shionogi Inc MULPLETA lusutrombopag TABLET;ORAL 210923-001 Jul 31, 2018 RX Yes Yes 9,427,402 ➤ Try a Free Trial Y ➤ Try a Free Trial
Shionogi Inc COGNEX tacrine hydrochloride CAPSULE;ORAL 020070-002 Sep 9, 1993 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial
Shionogi Inc SYMPROIC naldemedine tosylate TABLET;ORAL 208854-001 Mar 23, 2017 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial
Shionogi Inc SYMPROIC naldemedine tosylate TABLET;ORAL 208854-001 Mar 23, 2017 RX Yes Yes RE46365 ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Shionogi Inc COGNEX tacrine hydrochloride CAPSULE;ORAL 020070-004 Sep 9, 1993 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

Subscribe to access the full database, or try a Free Trial

Expired US Patents for Shionogi Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Shionogi Inc DORIBAX doripenem INJECTABLE;INTRAVENOUS 022106-002 Oct 5, 2010 5,317,016 ➤ Try a Free Trial
Shionogi Inc COGNEX tacrine hydrochloride CAPSULE;ORAL 020070-004 Sep 9, 1993 4,631,286 ➤ Try a Free Trial
Shionogi Inc COGNEX tacrine hydrochloride CAPSULE;ORAL 020070-002 Sep 9, 1993 4,631,286 ➤ Try a Free Trial
Shionogi Inc RYBIX ODT tramadol hydrochloride TABLET, ORALLY DISINTEGRATING;ORAL 021693-001 May 5, 2005 5,464,632 ➤ Try a Free Trial
Shionogi Inc COGNEX tacrine hydrochloride CAPSULE;ORAL 020070-002 Sep 9, 1993 4,816,456 ➤ Try a Free Trial
Shionogi Inc COGNEX tacrine hydrochloride CAPSULE;ORAL 020070-001 Sep 9, 1993 4,631,286 ➤ Try a Free Trial
Shionogi Inc COGNEX tacrine hydrochloride CAPSULE;ORAL 020070-004 Sep 9, 1993 4,816,456 ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for SHIONOGI INC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Lotion 5% ➤ Subscribe 2016-04-11
➤ Subscribe Injection 250 mg/vial and 500 mg/vial ➤ Subscribe 2011-10-11

Supplementary Protection Certificates for Shionogi Inc Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1270575 333 Finland ➤ Try a Free Trial
0528678 2009/002 Ireland ➤ Try a Free Trial PRODUCT NAME: DORIPENEM.; REGISTRATION NO/DATE: EU/1/08/467/001 20080725
1307486 SPC/GB12/030 United Kingdom ➤ Try a Free Trial PRODUCT NAME: CYCLO((4R)-4-(2-AMINOETHYLCARBAMOYLOXY)-L-PROLYL-L-PHENYLGLYCYL-D-TRYPTOPHYL-L-LYSYL-4-O-BENZYL-L-TYROSYL-L-PHENYLALANYL-)), PASIREOTIDE, OR SALTS THEREOF; REGISTERED: UK EU/1/12/753/001-012 20120424
0658161 SPC/GB01/003 United Kingdom ➤ Try a Free Trial PRODUCT NAME: N-(4-(2(N-METHYL-N-(2-PYRIDYL)AMINO)ETHOXY)BENZYL)THIAZOLIDINE-2,4-DIONE MALEIC ACID, "ROSIGLITAZONE MALEATE", ITS TAUTOMERS AND PHARMACEUTICALLY ACCEPTABLE SOLVATES; REGISTERED: CH 55176 02 19990929; CH 55176 03 19990929; CH 55176 04 19990929; UK EU/1/00/137/001 20000711; UK EU/1/00/137/002 20000711; UK EU/1/00/137/003 20000711; UK EU/1/00/137/004 20000711; UK EU/1/00/137/005 20000711; UK EU/1/00/137/006 20000711; UK EU/1/00/137/007 20000711; UK EU/1/00/137/008 20000711; UK EU/1/00/137/009 20000711; UK EU/1/00/137/010 20000711; UK EU/1/00/137/011 20000711; UK EU/1/00/137/012 20000711
0528678 SPC/GB09/006 United Kingdom ➤ Try a Free Trial PRODUCT NAME: DORIPENEM; REGISTERED: UK EU/1/08/467/001 20080725
1506193 SPC/GB14/044 United Kingdom ➤ Try a Free Trial PRODUCT NAME: RIOCIGUAT, I.E. METHYL N-(4,6-DIAMINO-2-(1-(2-FLUOROBENZYL)-1H-PYRAZOLO (3,4-B)PYRIDIN-3-YL)-5-PYRIMIDINYL(METHYL)CARBAMATE,OR A PHARMACEUTICALLY ACCEPTABLE SALT OR HYDRATE THEREOF.; REGISTERED: UK EU/1/13/907 20140331
0306228 SPC/GB01/002 United Kingdom ➤ Try a Free Trial PRODUCT NAME: 5-(4-(2-(N-METHYL-N-(2-PYRIDYL)AMINO)ETHOXY) BENZYL)-2,4-THIAZOLIDINEDIONE, "ROSIGLITAZONE" ITS TAUTOMERS, PHARMACEUTICALLY ACCEPTABLE SALTS, SUCH AS THE MALEATE, AND PHARMACEUTICALLY ACCEPTABLE SOLVATES.; REGISTERED: CH 55176 02 19990929; CH 55176 03 19990929; CH 55176 04 19990929; UK EU/1/00/137/001 20000711; UK EU/1/00/137/002 20000711; UK EU/1/00/137/003 20000711; UK EU/1/00/137/004 20000711; UK EU/1/00/137/005 20000711; UK EU/1/00/137/006 20000711; UK EU/1/00/137/007 20000711; UK EU/1/00/137/008 20000711; UK EU/1/00/137/009 20000711; UK EU/1/00/137/010 20000711; UK EU/1/00/137/011 20000711; UK EU/1/00/137/012 20000711
Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
US Department of Justice
Express Scripts
Boehringer Ingelheim
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.